“…Recently, a number of studies have compared and validated smaller panels ( n = 1–7) of SARS-CoV-2 serological tests for diagnostic use [ 9 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 ]. In the present study, we intended to systematically cross-compare a large number of SARS-CoV-2 serological tests, and thus analyzed a broad panel of SARS-CoV-2 ECLIA-, ELISA-, and LFA-based tests which were available in May 2020, using a relatively large number of sera from patients with COVID-19, and from controls.…”